Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current financial resources to fund operations into fiscal 2029.